Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Primary Pulmonary Lymphomas

Piña-Oviedo, Sergio MD; Weissferdt, Annikka MD; Kalhor, Neda MD; Moran, Cesar A. MD

doi: 10.1097/PAP.0000000000000090
Review Articles
Buy

Primary lung lymphoma (PLL) is a rare disease that comprises <0.5% of all primary lung tumors. It is defined as lymphoma confined to the lung with or without hilar lymph node involvement at the time of diagnosis or up to 3 months thereafter. Patients with PLL may be asymptomatic or manifest nonspecific clinical symptoms, for example, cough, chest pain, and dyspnea. Some individuals may be immunosupressed or have an autoimmune disorder. Radiologically, PLL can mimic pneumonia, lung carcinoma, or metastasis, and therefore, histologic confirmation is mandatory for definitive diagnosis. Primary lung marginal zone lymphoma of mucosa-associated lymphoid tissue type comprises 70% to 80% of cases. Less common B-cell lymphomas include diffuse large B-cell lymphoma, lymphomatoid granulomatosis (LyG), plasmacytoma, and other small lymphocytic lymphomas. PLLs of T-cell origin, largely represented by anaplastic large cell lymphoma, are extremely rare. LyG is an Epstein-Barr virus (EBV)-driven B-cell lymphoid neoplastic proliferation rich in T cells that produces vasculitis. The disease may present at different stages of progression. Differential diagnosis of PLL varies according to the lymphoma subtype: pulmonary mucosa-associated lymphoid tissue lymphoma should be distinguished from reactive inflammatory conditions, whereas high-grade lymphomas may resemble poorly differentiated lung carcinoma, metastatic disease, and other lymphomas. LyG can resemble inflammatory, infectious, and other lymphoid neoplastic processes. A panel of immunohistochemical markers, flow cytometry, and molecular methods are necessary to confirm the diagnosis in the majority of cases. In this article we review the clinical, radiologic, pathologic, and molecular characteristics of several B-cell and T-cell PLLs with exception of Hodgkin lymphoma and posttransplant lymphoproliferative disorder.

Department of Pathology and Thoracic Pathology, M. D. Anderson Cancer Center, Houston, TX

The authors have no funding or conflicts of interest to disclose.

Reprints: Cesar A. Moran, MD, Department of Pathology and Thoracic Pathology, M. D. Anderson Cancer Center, 1515 Holcombe Blvd. Suite 3595, Houston, TX 77030 (e-mail: cesarmoran@mdanderson.org).

All figures can be viewed online in color at http://www.anatomicpathology.com.

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.